Zoetis Inc. (ZTS)
USD 167.01
(-2.21%)
USD 167.01
(-2.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.29 Billion USD | -11.66% |
| 2022 | 10.52 Billion USD | 12.46% |
| 2021 | 9.35 Billion USD | -4.88% |
| 2020 | 9.83 Billion USD | 11.3% |
| 2019 | 8.83 Billion USD | 2.85% |
| 2018 | 8.59 Billion USD | 26.35% |
| 2017 | 6.8 Billion USD | 10.57% |
| 2016 | 6.15 Billion USD | -9.85% |
| 2015 | 6.82 Billion USD | 29.45% |
| 2014 | 5.27 Billion USD | -5.83% |
| 2013 | 5.59 Billion USD | 151.96% |
| 2012 | 2.22 Billion USD | 12.46% |
| 2011 | 1.97 Billion USD | 1.8% |
| 2010 | 1.94 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 9.29 Billion USD | 0.01% |
| 2024 Q3 | 9.12 Billion USD | -0.89% |
| 2024 Q2 | 9.2 Billion USD | -0.98% |
| 2023 Q2 | 9.12 Billion USD | -1.46% |
| 2023 Q1 | 9.26 Billion USD | -11.97% |
| 2023 Q4 | 9.29 Billion USD | 2.91% |
| 2023 Q3 | 9.03 Billion USD | -1.05% |
| 2023 FY | 9.29 Billion USD | -11.66% |
| 2022 Q2 | 9.19 Billion USD | -0.13% |
| 2022 FY | 10.52 Billion USD | 12.46% |
| 2022 Q4 | 10.52 Billion USD | 16.76% |
| 2022 Q3 | 9.01 Billion USD | -1.94% |
| 2022 Q1 | 9.2 Billion USD | -1.65% |
| 2021 FY | 9.35 Billion USD | -4.88% |
| 2021 Q4 | 9.35 Billion USD | 3.68% |
| 2021 Q3 | 9.02 Billion USD | -7.13% |
| 2021 Q2 | 9.71 Billion USD | 0.13% |
| 2021 Q1 | 9.7 Billion USD | -1.34% |
| 2020 Q3 | 10.11 Billion USD | 0.36% |
| 2020 Q2 | 10.08 Billion USD | 14.89% |
| 2020 Q4 | 9.83 Billion USD | -2.79% |
| 2020 FY | 9.83 Billion USD | 11.3% |
| 2020 Q1 | 8.77 Billion USD | -0.7% |
| 2019 Q3 | 8.59 Billion USD | 0.22% |
| 2019 FY | 8.83 Billion USD | 2.85% |
| 2019 Q4 | 8.83 Billion USD | 2.83% |
| 2019 Q1 | 8.56 Billion USD | -0.3% |
| 2019 Q2 | 8.57 Billion USD | 0.11% |
| 2018 Q3 | 8.34 Billion USD | 25.98% |
| 2018 Q4 | 8.59 Billion USD | 3.01% |
| 2018 FY | 8.59 Billion USD | 26.35% |
| 2018 Q2 | 6.62 Billion USD | -1.4% |
| 2018 Q1 | 6.71 Billion USD | -1.25% |
| 2017 Q3 | 7.26 Billion USD | 20.03% |
| 2017 Q1 | 6.01 Billion USD | -2.21% |
| 2017 FY | 6.8 Billion USD | 10.57% |
| 2017 Q4 | 6.8 Billion USD | -6.45% |
| 2017 Q2 | 6.05 Billion USD | 0.7% |
| 2016 Q2 | 6.14 Billion USD | -1.9% |
| 2016 Q3 | 6.11 Billion USD | -0.49% |
| 2016 Q4 | 6.15 Billion USD | 0.54% |
| 2016 FY | 6.15 Billion USD | -9.85% |
| 2016 Q1 | 6.26 Billion USD | -8.15% |
| 2015 Q3 | 5.43 Billion USD | 0.67% |
| 2015 FY | 6.82 Billion USD | 29.45% |
| 2015 Q4 | 6.82 Billion USD | 25.59% |
| 2015 Q2 | 5.39 Billion USD | 5.29% |
| 2015 Q1 | 5.12 Billion USD | -2.75% |
| 2014 Q3 | 5.13 Billion USD | -1.93% |
| 2014 Q4 | 5.27 Billion USD | 2.57% |
| 2014 FY | 5.27 Billion USD | -5.83% |
| 2014 Q1 | 5.3 Billion USD | -5.22% |
| 2014 Q2 | 5.23 Billion USD | -1.23% |
| 2013 Q2 | 5.43 Billion USD | 0.37% |
| 2013 Q3 | 5.39 Billion USD | -0.83% |
| 2013 Q1 | 5.41 Billion USD | 143.94% |
| 2013 FY | 5.59 Billion USD | 151.96% |
| 2013 Q4 | 5.59 Billion USD | 3.76% |
| 2012 FY | 2.22 Billion USD | 12.46% |
| 2012 Q1 | 1.95 Billion USD | -0.96% |
| 2012 Q2 | 1.86 Billion USD | -4.45% |
| 2012 Q3 | 1.79 Billion USD | -3.96% |
| 2012 Q4 | 2.22 Billion USD | 23.73% |
| 2011 Q4 | 1.97 Billion USD | 0.0% |
| 2011 FY | 1.97 Billion USD | 1.8% |
| 2010 FY | 1.94 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 3.45 Billion USD | -169.221% |
| Bausch Health Companies Inc. | 27.43 Billion USD | 66.116% |
| Catalent, Inc. | 6.14 Billion USD | -51.163% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -683.991% |
| Elanco Animal Health Incorporated | 8.13 Billion USD | -14.203% |
| Perrigo Company plc | 6.04 Billion USD | -53.86% |
| Teva Pharmaceutical Industries Limited | 35.35 Billion USD | 73.708% |